- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01954524
A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis
November 9, 2022 updated by: University of Maryland, Baltimore
Safety and tolerability of a single dose intravenous bolus injection of Sildenafil in patients with moderate to severe cirrhosis and kidney disease will be determined.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
2
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland, Baltimore
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Subjects will be eligible for the study if they meet the following inclusion criteria:
- Cirrhosis. Diagnosis of cirrhosis will be based on either liver biopsy OR clinical characteristics (e.g. history of ascites or encephalopathy or esophageal varices or gastric varices or splenomegaly or spider angioma or any clinical sign of portal hypertension/cirrhosis), laboratory (e.g. history of thrombocytopenia or history of APRI (Reference: Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26) [Aspartate aminotransferase (AST) to platelet ratio index] score consistent with cirrhosis or history of abnormal liver function tests) and abdominal imaging (Magnetic Resonance Imaging or Computed Tomography or ultrasound of the abdomen) data
- CTP Class B or C cirrhosis
- Age 18 years or older at the time of enrollment
- Variceal screening with an upper endoscopy within 1 year before enrollment
- Renal dysfunction [GFR ≥ 15 and < 60 ml/min/1.73m2 estimated by 6-variable MDRD equation (Reference: Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-54)]
- Hemoglobin level ≥ 8 mg/dl within 4 weeks before enrollment
- Serum sodium level ≥ 125 mmol/L within 4 weeks before enrollment
Subjects will be excluded if they have any of the following:
- Inability to provide informed consent
- Women who are pregnant, breast-feeding, or contemplating pregnancy
- Treatment with organic nitrates, ritonavir, erythromycin, saquinavir, ketoconazole, itraconazole, cimetidine, bosentan, rifampin, Sildenafil or any other PDE-5 inhibitors, alpha-blockers, and anticoagulants within 7 days before enrollment
- Hypersensitivity or allergy to Sildenafil or any component of Sildenafil
- Previous reaction to PDE-5 inhibitors including, but not limited to Sildenafil, Vardenafil, Tadalafil, Avanafil (Myocardial infarction, ventricular arrhythmia, sudden cardiac death, cerebrovascular hemorrhage, transient ischemic attack, stroke, transient global amnesia, subarachnoid and intracerebral hemorrhages, seizure, recurrence in seizures, pulmonary hemorrhage, sudden decrease of hearing, loss of hearing, anxiety, prolonged erection, priapism, ocular redness, ocular burning, diplopia, temporary vision loss/decreased vision, ocular swelling, ocular pressure, increased intraocular pressure, retinal problems in the eye, vitreous detachment, vitreous traction, paramacular edema, non-arteritic anterior ischemic optic neuropathy)
- History of untreated severe left ventricular outflow obstruction (e.g. aortic stenosis, idiopathic hypertrophic subaortic stenosis)
- History of pulmonary veno-occlusive disease
- History of unstable angina, myocardial infarctus, life-threatening arrhythmia or stroke within 6 months before enrollment
- History of retinitis pigmentosa
- Anatomical deformation of the penis (Peyronie's disease, angulation, cavernosal fibrosis)
- History of sickle cell anemia, multiple myeloma or leukemia
- Renal failure treated with dialysis
- Cognitive impairment based on IRB "evaluation to sign consent form"
- Transjugular intrahepatic porto-systemic shunt placement
- Previous kidney or liver transplantation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IV bolus injection of Sildenafil
CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil.
CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil.
|
Dose escalation will be performed (in different participants). The doses will be as follows: CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with "suspected adverse reaction" of IV Sildenafil that is both "serious" and "unexpected" as a measure of safety and tolerability.
Time Frame: The total time to assess the primary outcome measure will be 48 hours after Sildenafil injection (starting from Sildenafil injection time until 48 hours after Sildenafil injection).
|
The total time to assess the primary outcome measure will be 48 hours after Sildenafil injection (starting from Sildenafil injection time until 48 hours after Sildenafil injection).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2014
Primary Completion (Actual)
October 1, 2015
Study Completion (Actual)
October 1, 2015
Study Registration Dates
First Submitted
September 13, 2013
First Submitted That Met QC Criteria
September 26, 2013
First Posted (Estimate)
October 1, 2013
Study Record Updates
Last Update Posted (Actual)
November 15, 2022
Last Update Submitted That Met QC Criteria
November 9, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HP-00057016
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cirrhosis
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
University Health Network, TorontoUnknown
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingPrimary Biliary CirrhosisChina
-
Northwestern UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
National Institute of Diabetes and Digestive and...National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruitingDecompensated CirrhosisIndia
-
Milton S. Hershey Medical CenterNot yet recruitingCirrhosis, Liver
-
Beijing 302 HospitalWuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, ChinaNot yet recruitingDecompensated CirrhosisChina
-
The Cleveland ClinicRecruiting
-
Xin ZengRecruitingDecompensated CirrhosisChina
Clinical Trials on IV bolus injection of Sildenafil
-
Aarhus University HospitalTerminatedAcute Kidney Injury | Fluid Overload | HypoperfusionDenmark
-
Korea University Guro HospitalHana Pharm. Co., LtdCompletedAnesthesia, General | AdultKorea, Republic of
-
Jules Bordet InstituteCompletedOvarian Cancer | Peritoneal CarcinomatosisBelgium
-
Aro BiotherapeuticsRecruiting
-
SOS Attaque CérébraleTerminatedInfarction, Middle Cerebral ArteryFrance
-
University Hospital, GhentWithdrawnPeritoneal Dialysis
-
Chinese University of Hong KongTerminatedGastrointestinal HemorrhageChina
-
Theravance BiopharmaCompletedBowel Diseases, Inflammatory | Intestinal DisordersUnited States
-
Radboud University Medical CenterCompletedShock | Septic | SevereNetherlands
-
AstraZenecaCompletedHealthy Elderly | Mild-Moderate Alzheimer's DiseaseUnited States